|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
|
Optimizing Salvage Radiation Therapy in Prostate Cancer: New AUA/ASTRO/SUO Guidelines
|
Todd Morgan, MD
Zach Klaassen speaks with Todd Morgan about innovative approaches in the management of prostate cancer post-prostatectomy. Dr. Morgan presents compelling new data on the prostate AI test, highlighting its use in identifying biochemical recurrence after prostatectomy.
|
|
|
|
|
|
|
|
|
|
|
|
PRIMORDIUM Trial Evaluates Apalutamide Plus ADT for High-Risk Biochemical Recurrence of Prostate Cancer After Prostatectomy
|
Boris Hadaschik, MD
Boris Hadaschik discusses the ongoing PRIMORDIUM phase three trial. The study explores the efficacy of adding six months of apalutamide to ADT in men with high-risk biochemical recurrence post-prostatectomy, evidenced by PSMA-PET imaging.
|
|
|
|
|
|
|
|
|
|
|
|
INDICATE Trial Seeks to Clarify the Role of PET Scans in Prostate Cancer Recurrence
|
Neha Vapiwala, MD, FACR, FASTRO
Alicia Morgans interviews Neha Vapiwala about the innovative phase three INDICATE trial, supported by the ECOG-ACRIN Group and NCI-designated cooperative groups. The trial focuses on patients with biochemical recurrence after prostatectomy, examining the impact of PET scans on treatment decisions.
|
|
|
|
|
|
|
|
|
|
|
| Biochemical Recurrence in Patients with Prostate Cancer after Primary Definitive Therapy: Next-Generation Imaging and Treatment Based on Risk Stratification |
| Judd Moul, MD, and Neal Shore, MD, FACS |
| Historically, conventional imaging techniques have been used for the assessment of clinical progression in biochemical recurrence. However, these imaging technologies have limited sensitivity at low PSA values. Next-generation imaging technologies may overcome the sensitivity limitations associated with low PSA values and offer improved diagnostic accuracy for identifying BCR compared with conventional imaging technologies. |
|
|
|
|
|
| AUA Guidelines: Salvage Therapy for Prostate Cancer |
| Todd Morgan, MD |
| Todd Morgan presents updated guidelines for salvage therapy in prostate cancer, emphasizing the need for timely intervention following biochemical recurrence after radical prostatectomy. The guidelines recommend early salvage radiation, particularly at low PSA levels, and the integration of advanced imaging techniques like PSMA-PET for better treatment planning. |
|
|
|
|
|
| The Added Value of Concomitant Whole-Pelvis Salvage Radiation Therapy in Oligo-Recurrent Prostate Cancer Patients Treated with Metastasis-Directed Therapy for Distant Positive Uptakes at PSMA PET
|
| Elio Mazzone, MD, Ph.D.
|
| Elio Mazzone presents a retrospective study evaluating the benefits of adding whole-pelvis salvage radiation therapy (WPRT) to metastasis-directed therapy (MDT) in prostate cancer patients with oligo-recurrent disease detected by PSMA PET. The study found that WPRT significantly reduced the risk of clinical recurrence, especially in patients with a higher risk of recurrence at three years. However, MDT alone was deemed sufficient for patients with a lower risk of recurrence.
|
|
|
|
|
|
|
|
|
|
|
| State of the Art Lecture: The Role of Adjuvant and Salvage Radiation Therapy for Prostate Cancer |
| Thomas Ahlering, MD |
| Thomas Ahlering delivers a lecture critically examining the role of adjuvant and salvage radiation therapy in prostate cancer. He reviews historical trials from the late 1980s and 1990s, highlighting ethical and design flaws, such as the inappropriate use of salvage radiation in control groups and questionable trial oversight. |
|
|
|
|
|
| 18F-rhPSMA-7 and 18F-flotufolastat PET-Guided Salvage Radiotherapy in Recurrent Prostate Cancer
|
| Isabel Rauscher, MD
|
| Isabel Rauscher presents a study comparing the outcomes of 18F-rhPSMA-7 or 18F-flotufolastat PET-guided salvage radiotherapy to conventional salvage radiotherapy in patients with recurrent prostate cancer after radical prostatectomy. The study found that PET-guided salvage radiotherapy resulted in longer biochemical failure-free survival, although the difference was not statistically significant, likely due to the small sample size.
|
|
|
|
|
|
| Intensification of ADT with Enzalutamide in High-Risk Patients with Biochemical Relapse Following Radical Prostatectomy Undergoing Salvage Radiation: Initial Results from RTOG 3506 (STEEL) |
| Edwin Posadas, MD, FACP |
| Edwin Posadas presented initial findings from the STEEL trial (RTOG 3506), which evaluated the intensification of androgen deprivation therapy with enzalutamide in high-risk prostate cancer patients experiencing biochemical relapse after radical prostatectomy and undergoing salvage radiation therapy. |
|
|
|
|
|
| COBRA: Assessment of Safety and Efficacy of 64Cu-SAR-bisPSMA in Patients with Biochemical Recurrence of Prostate Cancer Following Definitive Therapy |
| Luke Nordquist, MD, FACP |
| The COBRA study demonstrated that 64Cu-SAR-bisPSMA is a safe and effective imaging agent for detecting prostate cancer lesions in patients with biochemical recurrence, identifying lesions as small as 2 mm and leading to treatment plan changes in nearly 50% of cases. The imaging showed increased detection rates and clinical impact, with only one minor adverse event reported. |
|
|
|
|
|
